Photobiomodulation for the management of xerostomia and oral mucositis in patients with cancer: a randomized clinical trial

Lasers Med Sci. 2023 Apr 15;38(1):101. doi: 10.1007/s10103-023-03760-y.

Abstract

To evaluate the applicability of photobiomodulation therapy (PBM-T) in the management of xerostomia and OM. Fifty-three patients with head and neck squamous cell carcinoma were randomized into two groups: Sham and PBM-T. The Sham group received artificial saliva and laser simulation, while the PBM-T group received artificial saliva and PBM-T. Xerostomia-related quality of life (QoL), the presence or absence of OM lesions, the decayed-missing-filled teeth (DMFT) index, and periodontal charts were evaluated. The results of the QoL questionnaire, DMFT index, and periodontal chart were analyzed with the Kruskal-Wallis test, followed by the Student-Newman-Keuls test, while OM findings were compared using the Mann-Whitney test. QoL scores significantly increased in the Sham group (p < 0.0001), denoting more severe xerostomia symptoms (p = 0.0074), and decreased in the PBM-T group, indicating no or very mild xerostomia. Higher grades of OM were found in the Sham group than the PBM-T group (p = 0.0001). There was no significant difference in DMFT index or periodontal charts between the groups (p > 0.05). PBM-T improved QoL in patients with head and neck cancer treated with radiotherapy, whether as radiation alone or as an adjunct to chemotherapy and surgery.

Keywords: Cancer; Chemotherapy; Oral mucositis; Photobiomodulation; Radiotherapy; Xerostomia.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Head and Neck Neoplasms* / complications
  • Head and Neck Neoplasms* / radiotherapy
  • Humans
  • Low-Level Light Therapy* / methods
  • Quality of Life
  • Saliva, Artificial
  • Stomatitis* / etiology
  • Stomatitis* / pathology
  • Stomatitis* / radiotherapy
  • Xerostomia* / etiology
  • Xerostomia* / radiotherapy

Substances

  • Saliva, Artificial